Referencia número: HY-N0172

Caffeic acid

Name: Caffeic acid
Brand: MedChemExpress
SKU: HY-N0172
Price: 31.00 USD
Availability: InStock
Rating: 5 (9 reviews)

9 Cited Publications

Revisión del cliente

Based on 9 publication(s) in Google Scholar

Caffeic acid is an inhibitor of both TRPV1 ion channel and 5-Lipoxygenase (5-LO).

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 99.92%
No. CAS: 331-39-5
Fòrmula: C₉H₈O₄
Peso molecular:180.16

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Caffeic acid Chemical Structure

No. CAS: 331-39-5

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (9)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Caffeic acid is an inhibitor of both TRPV1 ion channel and 5-Lipoxygenase (5-LO).

IC₅₀ & Target

5-LO

Ver todos los productos específicos de isoformas TRP Channel :

Ver todos los productos específicos de isoformas Lipoxygenase :

Ver todos los productos específicos de isoformas Endogenous Metabolite :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	1 x 10³ μM Compound: 129	Inhibition of EGFR in human A431 cells Inhibition of EGFR in human A431 cells	[PMID: 1479375]
A549	IC₅₀	>100 μM Compound: CA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26638042]
A549	IC₅₀	0.5 mM Compound: Caffeic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay	[PMID: 27162124]
A549	IC₅₀	0.7 mM Compound: Caffeic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay	[PMID: 27162124]
A549	IC₅₀	0.7 mM Compound: Caffeic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27162124]
AGS	IC₅₀	129 μM Compound: 8	Cytotoxicity against human AGS cells after 96 hrs by MTT assay Cytotoxicity against human AGS cells after 96 hrs by MTT assay	[PMID: 23746477]
B16-F10	IC₅₀	>100 μM Compound: CA	Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26638042]
BALB/3T3	IC₅₀	553.8 μM Compound: 12	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
BMDC	IC₅₀	>50 μM Compound: 3	Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA Inhibition of LPS-induced IL-12 p40 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA	[PMID: 25769817]
BMDC	IC₅₀	>50 μM Compound: 3	Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA Inhibition of LPS-induced IL-6 production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA	[PMID: 25769817]
BMDC	IC₅₀	>50 μM Compound: 3	Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA Inhibition of LPS-induced TNF-alpha production in wild-type C57BL/6 mouse BMDC pretreated with compound for 1 hr before LPS treatment measured 16 hrs by ELISA	[PMID: 25769817]
BMDM	IC₅₀	41 μM Compound: Caffeic acid	Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base	[PMID: 31257875]
Caco-2	IC₅₀	>100 μM Compound: CA	Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 26638042]
EA.hy 926	EC₅₀	12.6 μM Compound: Caffeic acid	Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay	10.1039/C4MD00022F
Erythrocyte	IC₅₀	0.75 mM Compound: 21	Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me	[PMID: 29631958]
Erythrocyte	IC₅₀	0.94 mM Compound: 21	Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet	[PMID: 29631958]
Flp-In-293	IC₅₀	124.55 nM Compound: 50	Reversal of paclitaxel resistance in human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition in presence of caffeic acid for 30 mins by fluorescence based assay Reversal of paclitaxel resistance in human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition in presence of caffeic acid for 30 mins by fluorescence based assay	[PMID: 35751979]
Flp-In-293	IC₅₀	198.04 nM Compound: 50	Reversal of vincristine resistance in human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition in presence of caffeic acid for 30 mins by fluorescence based assay Reversal of vincristine resistance in human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition in presence of caffeic acid for 30 mins by fluorescence based assay	[PMID: 35751979]
Flp-In-293	IC₅₀	596.9 nM Compound: 50	Reversal of doxorubicin resistance in human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition in presence of caffeic acid for 30 mins by fluorescence based assay Reversal of doxorubicin resistance in human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition in presence of caffeic acid for 30 mins by fluorescence based assay	[PMID: 35751979]
HCT-116	IC₅₀	29.73 μM Compound: 8	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 23746477]
HEK293	IC₅₀	25 μM Compound: Caf.Ac	Inhibition of human 5LOX expressed in HEK293 cells Inhibition of human 5LOX expressed in HEK293 cells	[PMID: 19152786]
HeLa	IC₅₀	2.54 mM Compound: 22, 3,4-dihydroxy-cinnamic acid	Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay	[PMID: 19520580]
HeLa	IC₅₀	44 μg/mL Compound: 2	Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA	[PMID: 19942440]
Hep 3B2	IC₅₀	10 nM Compound: 3, CA	Inhibition of MMP9 in human Hep3B cells using gelatin as substrate Inhibition of MMP9 in human Hep3B cells using gelatin as substrate	[PMID: 23375794]
HT-22	EC₅₀	>10000 μM Compound: Caffeic acid	Inhibition of glutamate-induced oxytosis of mouse hippocampal HT22 cells Inhibition of glutamate-induced oxytosis of mouse hippocampal HT22 cells	[PMID: 16392814]
HT-22	EC₅₀	77.1 μM Compound: 30	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]
HT-29	IC₅₀	27.16 μM Compound: 8	Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 23746477]
HT-29	IC₅₀	>100 μM Compound: CaA	Growth inhibition of human HT-29 cells after 48 hrs by MTT assay Growth inhibition of human HT-29 cells after 48 hrs by MTT assay	[PMID: 27783972]
LNCaP	IC₅₀	>100 μM Compound: 1	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay	[PMID: 24080105]
MCF7	IC₅₀	>550 μM Compound: Caffeic acid	Cytotoxicity against human MCF7 cells assessed as [3H]-hypoxanthine incorporation after 48 hrs Cytotoxicity against human MCF7 cells assessed as [3H]-hypoxanthine incorporation after 48 hrs	[PMID: 20954722]
MDA-MB-231	IC₅₀	>100 μM Compound: CaA	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27783972]
MDCK	EC₅₀	>100000 nM Compound: CA	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect	[PMID: 22963087]
MOLM-13	IC₅₀	6.4 μM Compound: 15	Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay	[PMID: 30370766]
MOLM-14	IC₅₀	>10 μM Compound: 15	Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay	[PMID: 30370766]
MT2	ED₅₀	>1389 μM Compound: caffeic acid	Concentration that inhibits Human Immunodeficiency Virus Type 1 (HIV-1)-induced death of MT-2 cells Concentration that inhibits Human Immunodeficiency Virus Type 1 (HIV-1)-induced death of MT-2 cells	[PMID: 9986720]
MT4	IC₅₀	>1 μM Compound: 5	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by p24 ELISA Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by p24 ELISA	[PMID: 27676157]
MV4-11	IC₅₀	>10 μM Compound: 15	Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay	[PMID: 30370766]
Oocyte	IC₅₀	16.7 μM Compound: Caf-COOH	Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique	[PMID: 23682762]
P388	GI₅₀	>25 μg/mL Compound: caffeic acid	Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 10785435]
PC-12	IC₅₀	75.8 μM Compound: Caffeic acid	Neuroprotection against amyloid beta (25 to 35)-induced cell death in rat PC12 cells preincubated for 3 hrs followed by amyloid beta addition measured after 24 hrs by MTT assay Neuroprotection against amyloid beta (25 to 35)-induced cell death in rat PC12 cells preincubated for 3 hrs followed by amyloid beta addition measured after 24 hrs by MTT assay	[PMID: 29107423]
PC-3	IC₅₀	>100 μM Compound: CA	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26638042]
Peritoneal macrophage	IC₅₀	>550 μM Compound: Caffeic acid	Cytotoxicity against mouse peritoneal macrophages assessed as cell viability after 48 hrs by hematocytometer Cytotoxicity against mouse peritoneal macrophages assessed as cell viability after 48 hrs by hematocytometer	[PMID: 20954722]
RAW264.7	EC₅₀	165.295 μM Compound: 1	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay	[PMID: 18667320]
RAW264.7	EC₅₀	3406 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 18667320]
RBL-1	IC₅₀	4.3 x 10^-5 M Compound: caffeic acid	In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined	[PMID: 8254620]
SH-SY5Y	EC₅₀	33.82 μM Compound: Caffeic acid	Neuroprotection against H2O2-induced cell death in human SH-SY5Y cells preincubated for 6 hrs followed by H2O2 addition and measured after 24 hrs by MTT assay Neuroprotection against H2O2-induced cell death in human SH-SY5Y cells preincubated for 6 hrs followed by H2O2 addition and measured after 24 hrs by MTT assay	[PMID: 30470490]
T47D	IC₅₀	2 nM Compound: Caffeic acid	Antiproliferative activity against human T47D cells after 5 days by MTT assay Antiproliferative activity against human T47D cells after 5 days by MTT assay	[PMID: 23228470]
U-937	IC₅₀	316.5 μM Compound: 19, CA	Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting	[PMID: 22925447]
U-937	CC₅₀	>2000 μM Compound: 19, CA	Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay	[PMID: 22925447]
U-937	EC₅₀	9.9 μM Compound: 5	Cytotoxicity against human U937 cells assessed as reduction in viability incubated for 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction in viability incubated for 24 hrs by MTT assay	[PMID: 26197161]
Vero	IC₅₀	>550 μM Compound: Caffeic acid	Cytotoxicity against african green monkey Vero cells assessed as [3H]-hypoxanthine incorporation after 48 hrs Cytotoxicity against african green monkey Vero cells assessed as [3H]-hypoxanthine incorporation after 48 hrs	[PMID: 20954722]

In Vitro

Caffeic acid has inhibitory effects on histamine-induced responses and the inhibitory effect of Caffeic acid is gradually increased when the concentration used for pretreatment is increased from 0.1 to 1 mM, similar to typical dose-dependent responses. Pretreatment of HEK293T-TRPV1 cells with 1 mM Caffeic acid results in significant inhibition of capsaicin-induced responses. When lower concentration of Caffeic acid is used, the inhibitory effect for capsaicin-induced responses is less evident. Calcium imaging experiments show that Caffeic acid incubation results in significant inhibition in histamine-sensitive dorsal root ganglion (DRG) neurons. Pretreatment with Caffeic acid (1 mM) results in a significant decrease in the percentage of responsive DRG neurons to histamine application from 12.5% to 2.1%. Pretreatment with 1 mM Caffeic acid dramatically blocks the allylisothiocyanate (AITC)-induced intracellular calcium increase in TRPA1-expressing cells. Caffeic acid is also able to block the AITC-induced activation of TRPA1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mice pretreated with Caffeic acid (500 mg/kg) exhibit significantly less histamine-induced scratching (30.50±10.87 bouts/1 h, n=6). It is further found that the lower dose of Caffeic acid (100 mg/kg) is not significantly effective in terms of anti-scratching effects in histamine-induced scratching, although there appears to be a tendency of reduction (49.40±12.35 bouts/1 h, n=5). The chloroquine induced scratching is significantly inhibited by pretreatment with 500 mg/kg of Caffeic acid (161.6±31.42 bouts/1 h, n=5)^[1].Caffeic acid significantly reduces the expression of 5-LO mRNA (P<0.01) dose-dependently in hippocampus. Compare with the ischemia-reperfusion (I/R) non-treated group, 5-LO protein expression is significantly reduced in the I/R-Caffeic acid group (P<0.05 or P<0.01), especially in the I/R-Caffeic acid group (50 mg/kg). Compare with the I/R non-treated group, the latency to find platform is significantly shortened in low- and high-dose Caffeic acid groups, the shortened platform latency is most evident in the I/R- Caffeic acid group (50 mg/kg) (P<0.01). In the low-dose Caffeic acid group, cell injury is still marked, the pyknosis ratio is (63.6±2.8)%, whereas in the high-dose Caffeic acid group, hippocampal neuron karyopyknosis is significantly reduced and the pyknosis ratio is (13.3±3.0)%^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 331-39-5
Appearance Solid
Peso molecular 180.16
Fòrmula C₉H₈O₄
Color Off-white to light yellow
SMILES

O=C(O)/C=C/C1=CC=C(O)C(O)=C1
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
- Phenols
- Polyphenols
Initial Source
- Plants
- other families
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (9)

All IFBio/Physico-chemical AssayIPIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Food Chem

Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]

2023 Mar 30;405(Pt A):134807. PMID: 36370576
Talanta

Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. [Abstract]

2020 Feb 1:208:120450. PMID: 31816725
Pestic Biochem Physiol

Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]

2025 Dec:215:106655. PMID: 41162045

Caffeic acid purchased from MedChemExpress. Usage Cited in: Pestic Biochem Physiol. 2025 Dec:215:106655. [Abstract]

Immunostaining with anti-mCherry antibody to detect the effect of Caffeic acid (2 mg/mL) on Methoprene-induced nuclear localization of Met at 96 h AEL. Caffeic acid effectively prevented the Methoprene-induced nuclear import of Met at 96 h AEL in the larvae of D. melanogaster Met-mCherry.

Caffeic acid purchased from MedChemExpress. Usage Cited in: Pestic Biochem Physiol. 2025 Dec:215:106655. [Abstract]

Caffeic acid (1–1000 μM) inhibited the Methoprene-induced JHRR-Luc expression and Met-Tai interaction in a dose-dependent manner.

Caffeic acid purchased from MedChemExpress. Usage Cited in: Pestic Biochem Physiol. 2025 Dec:215:106655. [Abstract]

Co-immunoprecipitation assays were performed to detect the effect of Caffeic acid (10 μM; 1 h) on the interaction between Met and Hsp83. Caffeic acid promoted the binding between Met and Hsp83.

Caffeic acid purchased from MedChemExpress. Usage Cited in: Pestic Biochem Physiol. 2025 Dec:215:106655. [Abstract]

The binding and competition curves of Met and Methoprene were shown. Caffeic acid (2 μM) inhibited the interaction between Met and Methoprene.

Caffeic acid purchased from MedChemExpress. Usage Cited in: Pestic Biochem Physiol. 2025 Dec:215:106655. [Abstract]

2 mg/mL Caffeic acid (0.5-2.0 mg/mL) resulted in significantly precocious pupation, and smaller pupae of O. furnacalis compared to controls.
Neurotox Res

Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]

2026 Mar 19;44(2):12. PMID: 41854817
Exp Cell Res

Caffeic acid attenuates irradiation-induced hematopoietic stem cell apoptosis through inhibiting mitochondrial damage. [Abstract]

2021 Dec 15;409(2):112934. PMID: 34801561
Fitoterapia

2026 Sep:193:107388. PMID: 42476424
SSRN

2026 May 25.
SSRN

2025 Jul 8.
Regulatory Research and Medicine Evaluation

2025.

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (555.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.5506 mL

27.7531 mL

55.5062 mL

5 mM

1.1101 mL

5.5506 mL

11.1012 mL

10 mM

0.5551 mL

2.7753 mL

5.5506 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (13.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (13.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (11.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[1]

To determine cell viability, MTT assay is performed. HEK293T cells are cultured in 96-well plate at 37°C, a day before so that the confluence of cell is 85 to 90% on the actual day of the experiment. On the day of the experiment the cells are treated with different concentration of Caffeic acid for 10 min. Control cells are treated only with media. After removing supernatant and washing with PBS, MTT reagent (5 mg/mL) is added directly to fresh media. Cells are then incubated at 37°C for additional 4 h followed by draining of the media and overnight storage in dark condition. The next day, DMSO is added to each well and mixed in shaker for 10 min after which plate is read using microplate recorder at 490 nm with a reference wavelength of 620 nm. The relative cell viability (%) is expressed as a percentage relative to the untreated control cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Rats are divided into five groups: the sham group (n=9), ischemia-reperfusion (I/R) non-treated group (n=9), I/R-Caffeic acid group (10 mg/kg) (n=9), I/R-Caffeic acid group (30 mg/kg) (n=9) and I/R- Caffeic acid group (50 mg/kg) (n=9). In I/R-Caffeic acid groups, the rats are administrated Caffeic acid at 10, 30, 50 mg/kg (prepared with 0.3% sodium carboxymethyl cellulose) by intraperitoneal injection at 30 min prior to ischemia. The sham group and I/R group are treated with an equal volume of 0.3% sodium carboxymethyl cellulose^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (278 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Pradhananga S, et al. Caffeic acid exhibits anti-pruritic effects by inhibition of multiple itch transmission pathways in mice. Eur J Pharmacol. 2015 Sep 5;762:313-21. [Content Brief]

[2]. Liang G, et al. The protective effect of caffeic acid on global cerebral ischemia-reperfusion injury in rats. Behav Brain Funct. 2015 Apr 18;11:18. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.5506 mL	27.7531 mL	55.5062 mL	138.7655 mL
	5 mM	1.1101 mL	5.5506 mL	11.1012 mL	27.7531 mL
	10 mM	0.5551 mL	2.7753 mL	5.5506 mL	13.8766 mL
	15 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2510 mL
	20 mM	0.2775 mL	1.3877 mL	2.7753 mL	6.9383 mL
	25 mM	0.2220 mL	1.1101 mL	2.2202 mL	5.5506 mL
	30 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	40 mM	0.1388 mL	0.6938 mL	1.3877 mL	3.4691 mL
	50 mM	0.1110 mL	0.5551 mL	1.1101 mL	2.7753 mL
	60 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	80 mM	0.0694 mL	0.3469 mL	0.6938 mL	1.7346 mL
	100 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL

Bioz

Keywords

Caffeic acid

9 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Caffeic acid

Publications Citing Use of MedChemExpress (MCE) Caffeic acid

Ver todos los productos específicos de isoformas TRP Channel

Ver todos los productos específicos de isoformas Lipoxygenase

Ver todos los productos específicos de isoformas Endogenous Metabolite